Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05548777 · ClinicalTrials.gov registry record
Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 5,480
- Enrollment target
NCT05548777 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 5,480 participants.
The verdict
NCT05548777 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 5,480 participants
- Enrollment target
Study Summary
This is an observational study based on data collected via an audit of electronic medical charts. The study population will include adult US patients treated with andexanet alfa or 4F-PCC during a hospitalization for an anticoagulation-related major bleed, and their characteristics, treatments and outcomes will be described.
Interventions
- DRUG Andexanet alfa
- DRUG 4F-PCC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,480 participants |
| Start Date | 2022-09-15 |
| Est. Completion | 2022-12-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05548777
The ClinicalTrials.gov registry entry for NCT05548777 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 5,480 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Andexanet alfa is the first listed.
NCT05548777 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05548777 about?
NCT05548777 is a clinical study titled "Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed". This is an observational study based on data collected via an audit of electronic medical charts. The study population will include adult US patients treated with andexanet alfa or 4F-PCC during a hospitalization for an anticoagulation-related major bleed, and their characteristics, treatments and o...
What is the current status of trial NCT05548777?
This trial is currently completed. The enrollment target is 5,480 participants. The study started on 2022-09-15. Estimated completion is 2022-12-20.
What interventions are being tested in trial NCT05548777?
The interventions under investigation include: Andexanet alfa (DRUG), 4F-PCC (DRUG).
Who is sponsoring clinical trial NCT05548777?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.